Metabolic surgery versus conventional therapy in type 2 diabetes

Alexander D. Miras; Carel W. le Roux

doi:10.1016/S0140-6736(21)00129-X

Metabolic surgery versus conventional therapy in type 2 diabetes

Alexander D. Miras, Carel W. le Roux

School of Biomedical Sciences

Research output: Contribution to journal › Comment/debate › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	256-257
Number of pages	2
Journal	The Lancet
Volume	397
Issue number	10271
DOIs	https://doi.org/10.1016/S0140-6736(21)00129-X
Publication status	Published (in print/issue) - 23 Jan 2021

Bibliographical note

Funding Information:
CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.

Keywords

Bariatric Surgery
Diabetes Mellitus, Type 2/drug therapy
Follow-Up Studies
Glycated Hemoglobin A/analysis
Humans

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(21)00129-X

Cite this

@article{50cb826e779b469199a21670000024cd,

title = "Metabolic surgery versus conventional therapy in type 2 diabetes",

keywords = "Bariatric Surgery, Diabetes Mellitus, Type 2/drug therapy, Follow-Up Studies, Glycated Hemoglobin A/analysis, Humans",

author = "Miras, {Alexander D.} and {le Roux}, {Carel W.}",

note = "Funding Information: CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.",

year = "2021",

month = jan,

day = "23",

doi = "10.1016/S0140-6736(21)00129-X",

language = "English",

volume = "397",

pages = "256--257",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10271",

}

TY - JOUR

T1 - Metabolic surgery versus conventional therapy in type 2 diabetes

AU - Miras, Alexander D.

AU - le Roux, Carel W.

N1 - Funding Information: CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.

PY - 2021/1/23

Y1 - 2021/1/23

KW - Bariatric Surgery

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Follow-Up Studies

KW - Glycated Hemoglobin A/analysis

KW - Humans

UR - http://www.scopus.com/inward/record.url?scp=85099631470&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)00129-X

DO - 10.1016/S0140-6736(21)00129-X

M3 - Comment/debate

C2 - 33485432

AN - SCOPUS:85099631470

SN - 0140-6736

VL - 397

SP - 256

EP - 257

JO - The Lancet

JF - The Lancet

IS - 10271

ER -

Metabolic surgery versus conventional therapy in type 2 diabetes

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Cite this